| CAS: | 67684-64-4 | |||
| 分子式: | C7H11NO4 | |||
| 分子量: | 173.17 | |||
| 中文名称: |
| |||
| 用途: | trans-ACPD 是一种代谢型受体激动剂,促进钙离子活动及产生内向电流。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| A877852 | MACKLIN | trans-ACPD | ≥98% | 430元/2mg; 922元/5mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||
储存:2-8℃ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| A155 | Sigma-Aldrich | trans-(±)-ACPD monohydrate | solid, ≥97% (NMR) | 2053.11元/5 MG; 24841.9元/100 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 包装 5, 25, 100 mg in glass bottle 生化/生理作用 Excitatory amino acid receptor agonist; selective for the metabotropic glutamate receptor subtype. 其他说明 Note: under IUPAC nomenclature, this compound is designated cis. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HY-19434 | MCE | trans-ACPD,67684-64-4_MCE(MedChemExpress) | 913元/10 mM * 1 mL in DMSO; 365元/1 mg; 830元/5 mg; 1304元/10 mg; 2608元/25 mg; 3913元/50 mg; 5870元/100 mg; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 trans-ACPDMCE 国际站:trans-ACPD 品牌:MedChemExpress (MCE) 货号:HY-19434 CAS 号:67684-64-4 生物活性: trans-ACPD 是一种代谢型受体激动剂,可引起培养的小脑浦肯野神经元钙动员和内向电流。 体外研究(In Vitro):兴奋性氨基酸 (EAA) 类似物激活与磷酸肌醇 (PI) 水解增加相关的受体。在这些研究中,从新生大鼠 (6-11 天大) 制备海马切片,以表征 EAA 类似物对这些受体的影响。引起半数最大刺激所需的反式 ACPD 浓度 (EC50 值) 为 51 μM。DL-2-Amino-3-phosphonopropionate (DL-AP3) 也可作为 PI 水解的抑制剂,由鹅膏蕈氨酸、使君子氨酸和反式 ACPD 刺激 (IC50 值为 480-850 μM)[2]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 体内研究(In Vivo):与鞘内注射生理盐水的动物相比,鞘内注射 NMDA、红藻氨酸和反式 ACPD、TNF-α 或 IL-1β 会导致小鼠出现显著 (pip) 处理的小鼠相比,用 GM (100 mg/kg,ip) 进行全身预处理显著 (p[3]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量:173.17 Formula:C7H11NO4 性状:固体 颜色:White to off-white 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:粉末 -20°C 3年 Animal Administration [3]:Mice[3]Male Swiss mice (25-35 g) are used. Intrathecal injections are given to fully conscious mice. Briefly, the animals are manually restrained, and a 30-gauge needle connected by a polyethylene tube to a 25 μL Hamilton gas-tight syringe is inserted through the skin and between the vertebrae into the subdural space of the L5-L6 spinal segments. Intrathecal injections (5 μL/site) are administered over a period of 5 s. Biting behaviour is defined as a single head movement directed at the flanks or hind limbs, resulting in contact of the animal's snout with the target organ. The nociceptive response is elicited by NMDA (450 pmol/site, a selective agonist of the NMDA glutamatergic ionotropic receptor), kainate (110 pmol/site, a selective agonist of the kainate subtype of glutamatergic ionotropic receptors), and trans-ACPD (50 nmol/site, a non-selective agonist of metabotropic glutamate receptors, which is active at group I and group II), TNF-α (0.1 pmol/site) and IL-1β (1 pmol/site) or saline (5 μL/site, i.t.). The amount of time the animal spent biting or licking the caudal region is taken as evidence of nociception and is evaluated following local post injections of the following agonists: NMDA (5 min), kainate (4 min), and trans-ACPD TNF-α, and IL-1β (15 min). Animals received GM (100 mg/kg, i.p.) 0.5 h before intrathecal injection of 5 μL of the drugs, while control animals received a similar volume of saline (10 mL/kg, i.p.). MCE尚未独立确认这些方法的准确性。 仅供参考。 提供质量检测报告:Data Sheet、SDS、COA、HNMR、产品使用指南 产品活性:trans-ACPD 是一种代谢型受体激动剂,促进钙离子活动及产生内向电流。 相关产品:Y-27632 dihydrochloride | Y-27632 dihydrochloride | Y-27632 dihydrochloride (Standard) | RSL3 | Eliglustat hemitartrate | SBE-β-CD | Doxorubicin hydrochloride | Doxorubicin hydrochloride (Standard) | Olaparib | Olaparib (Standard) | Teriparatide | Lazertinib 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||